Xencor Inc (XNCR)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $23.52
- As of
Kresmion compiles this page from XNCR's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Xencor Inc (XNCR): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-05.
See the full XNCR dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for XNCR on one page. Preview it with sample data, then open it live with a free account.
Preview the XNCR dossierActive signals for XNCR
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +180% to XNCR (2026Q2)
- mediumNEW_POSITION
D. E. Shaw & Co., Inc. new position in XNCR
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 65.9%, EPS $-0.29 vs $-0.8513 estimate
- highINSTITUTIONAL_SURGE
TWO SIGMA INVESTMENTS, LP added +200% to XNCR (2026Q1)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 44.2% - EPS $-0.41 vs $-0.7347 estimate
FREE, NO ACCOUNT
Every signal on XNCR, as it fires
You are seeing 5 of 8 signals recorded on XNCR since 2026-05-30.
The five above landed across 4 days. The other 3 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in XNCR (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| MILLENNIUM MANAGEMENT LLCCUSIP 98401F105 · 2026Q2 | $13.7M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 98401F105 · 2026Q2 | $13.2M | 0.01% | , |
| CITADEL ADVISORS LLCCUSIP 98401F105 · 2026Q2 | $3.1M | 0.00% | , |
| Point72 Asset Management, L.P.CUSIP 98401F105 · 2026Q2 | $1.2M | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 98401F105 · 2026Q2 | $813K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, XNCR
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
XNCR against its peers
XNCR's operating margin of -141.4% ranks in the 53rd percentile of 15 Biotechnology sub-industry peers, fiscal periods ending between 2025-06-30 and 2025-12-31.
| Metric | XNCR | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 126M USD | 68.6M USD | 72 | 15 |
| Operating margin | -141.4% | -148.6% | 53 | 15 |
| Net margin | -73.2% | -311.7% | 68 | 16 |
| Return on equity | -14.5% | -49.6% | 78 | 19 |
| 1 year | 68.5% | -5.2% | 73 | 19 |
Peers (22): BHVN, ZYME, MESO, URGN, AGIO, SRPT, ZBIO, VIR, SEPN, ABSI, LKFT, PVLA, FBRX, NTLA, VCEL, NVAX, MLYS, STOK, VRDN, QURE, CMPS, VERA. Left out: GENB (no annual filing), ADRX (no annual filing), BRVE (no annual filing). Fiscal periods ending between 2025-06-30 and 2025-12-31. Every figure is one full fiscal year read from one annual filing (XNCR: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow XNCR on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to XNCR for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.